AzTrials
AzTrials

Pre-EclampsiaNCT02721771

Acid-Base and Point of Care Ultrasound in Severe Preeclampsia

An observational study of Pre-Eclampsia, run by University of Cape Town at 1 site in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Preeclampsia remains a leading cause of maternal morbidity and mortality, in both the developed and developing world. It is a complex, multisystem disease which, in its severe form, affects the cardiovascular, renal, hepatic, neurological and haematological systems. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Pre-Eclampsia
What is being tested?
Ultrasound examination
Type of treatment
Surgery or procedure
How many people
97 participants
Where
1 siteSouth Africa
Study dates
Mar 2016to Oct 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Women diagnosed with late onset severe preeclampsia according to the definition of the Royal college of obstetricians and gynaecologists.

Who may be able to join

  • age > 18years
  • previously healthy
  • new late onset severe preeclampsia

Who cannot join

  • labour
  • chronic obstructive pulmonary disease (COPD)
  • collagen disorder
  • ho lithium intoxication
  • ho of methanol, ethanol, salicylates ingestion
  • HIV
Show all 14Show fewer
  • regular ingestion of antacids
  • chronic renal disease
  • chronic hepatic disease
  • urinary tract infection (UTI),
  • infection, sepsis
  • BMI>50
  • acute asthma
  • unable to provide consent

Trial locations and contacts

1 site in 1 country.

South Africa1 site
  • University of Cape Town

    Cape Town, Western Cape/Observatory, 7925

Other trials in South Africa

About this study

Official title: Acid-base Disturbances and Ultrasound Markers as Biological Predictors of Maternal and Fetal Outcomes in Severe Late Onset Preeclampsia

Preeclampsia remains a leading cause of maternal morbidity and mortality, in both the developed and developing world. It is a complex, multisystem disease which, in its severe form, affects the cardiovascular, renal, hepatic, neurological and haematological systems. The University of Cape Town-associated medical institutions alone were responsible for the treatment of 800 women in 2014, who were classified as having preeclampsia with severe features. Given the complexity of the disease, anesthetic management for Caesarean section in these patients remains very challenging.

Recent studies have begun to demonstrate novel markers of preeclampsia severity, including point-of-care ultrasound (POC-US) and acid-base (AB) abnormalities. For example, pilot studies have demonstrated that approximately 25% of women diagnosed with severe preeclampsia show signs of increased intracranial pressure and elevated lung water as evaluated by point of care ultrasound. These findings could serve as noninvasive markers of disease severity, and thus may be used to predict maternal and fetal outcome in preeclamptic women. Point of care ultrasound is playing an increasing role in perioperative diagnosis, and newer, less expensive devices are continuously being developed, and will in all likelihood play an important role in South Africa in the near future.

In a recent trial performed at the University of Cape Town, a comprehensive acid-base analysis in severe preeclamptic women demonstrated significant abnormalities in independent acid-base determinants. In addition, strong indications were found that changes in acid-base status in preeclampsia are more pronounced earlier in pregnancy and are associated with urgent deliveries. As in other clinical arenas in critically ill patients, acid-base abnormalities are associated with increased lung water, increased intracranial pressure, and outcome, and we hypothesize that similar associations might be found in severe preeclamptic women. Therefore, one aim of this study is to evaluate the association of venous acid base abnormalities (an inexpensive and readily available test) observed in late onset severe preeclampsia and organ manifestations identified with ultrasound, a well-validated and robust tool for identifying these manifestations. Investigators will further examine the association between ultrasound findings and/or venous acid-base abnormalities with urgent delivery. It is intended to do a subsequent comparison between early- and late onset preeclampsia, when a suitable tertiary site has been identified.

Read the detailed description
  1. Introduction / Specific Aims Preeclampsia is a major cause of maternal mortality (15-20 % in developed countries) and acute and long-term morbidity for the mother and newborn. It is a multi-system disorder characterised by abnormal vascular response to placentation, associated with increased systemic vascular resistance, enhanced platelet aggregation, activation of the coagulation system, and endothelial dysfunction. Preeclampsia is defined by a number of signs and symptoms, but is characterized by multi-organ changes that encompass the central nervous system (CNS), lungs, liver, kidneys, systemic vasculature, coagulation, and the heart .

Derived from other clinical arenas of intensive care medicine, new potential markers of disease severity in women diagnosed with preeclampsia have recently been identified. Using noninvasive point-of-care (POC) ultrasound, pulmonary interstitial edema and raised intracranial pressure were identified in 25% and 20% respectively of women showing features of severe preeclampsia. In addition, echocardiographic and laboratory studies in women diagnosed with preeclampsia indicate an incidence of diastolic dysfunction and increased left ventricular end-diastolic pressure (LVEDP) in up to 30%. These findings could have a significant impact on maternal outcome and the detailed methodology of anesthesia care for the parturient with severe preeclampsia (PreE), including the mode of anesthesia, positioning of the patient, fluid management, and hemodynamic goals.

In a recent investigation performing a comprehensive physicochemical acid/base analysis in pre-eclamptic women (AB-PreE-Trial), the presence of simultaneous hypoalbuminaemic alkalosis and hyperchloraemic acidosis was identified. In addition, investigators found indications that hypoalbuminaemic alkalosis is more marked in early versus late onset disease and is associated with mode of delivery. In other critical care arenas it has been shown that reduced albumin and acid-base abnormalities are associated with pulmonary interstitial edema, elevated intracranial pressure (ICP), and poor clinical outcomes. Venous acid-base analysis may therefore be a widely available and inexpensive marker of pulmonary interstitial edema and elevated ICP in preeclampsia, with potentially important impact on anesthesia care. Therefore, one aim is to evaluate the association between elevated base excess to changes in albumin concentration (BE(Alb)) with pulmonary interstitial edema and increased ICP (both evaluated with non-invasive ultrasound) in patients with late onset severe preeclampsia. Investigators will further evaluate for an association with urgent delivery (fetal or maternal indication).

Long-term goal will be to use findings to guide clinical decision-making by anaesthetists to identify individual patients with acute organ system failures, helping better plan anaesthetic management during Cesarean delivery. Also, the findings from a larger future study could predict maternal and fetal complications, and show differences between early- and late onset disease. This should be of significant future benefit in the South African context, where preeclampsia is a leading cause of maternal morbidity and mortality.

II. Aims

Aim 1: To explore the association between ultrasound findings and/or venous acid-base abnormalities, with urgent delivery.

It is hypothesised that patients with acid-base changes secondary to albumin, interstitial edema and/or elevated ICP will experience a greater proportion of urgent deliveries, compared to patients without these abnormalities.

Aim 2: To determine the association between pulmonary interstitial edema and increased ICP with changes in BE(Alb).

Primary Hypothesis: Based on prior studies showing the association of low albumin with increased extravascular lung water and worse cerebral edema it is hypothesised that the mean BE(Alb) will be higher in patients with pulmonary interstitial edema and increased ICP (assessed with POC ultrasound), compared to patients without interstitial edema and normal ICP. Point-of-care ultrasound is a validated method of identifying both pulmonary interstitial edema and elevated ICP.

Sample size calculations:

Aim 1: Among patients with late onset disease, prior data suggests that 30% of patients will have a BE(Alb) > 4 meq/L, with a rate of fetal distress >70% in this population, as compared to a fetal distress rate of 25% in women with a BE(Alb) < 4 meq/L. Based on the observation that 70% of women in late onset disease will have a BE(Alb) < 4 meq/L at diagnosis, and considering an alpha level of 0.05 and power of 0.8, 70 patients will be needed to reject null hypothesis of predicting delivery status with BE(alb) > 4mEq/L.

Aim 2: In addition, available data suggests that the incidence of elevated intracranial pressure and interstitial pulmonary edema diagnosed by ultrasound in severe preeclampsia is approximately 25%, and an elevated BE (Alb) is found in approximately 30% of patients with severe preeclampsia. Prior data in critically ill patients indicates a mean albumin of 2.8 g/dL (SD 0.7) in patients with normal lung water, compared a mean albumin of 2.2 g/dL (SD 0.7) in patients with increased lung water. When converted to the BE (Alb) scale (assuming a mean pH of 7.4) and with the biologically plausible assumption of a similar relationship with ICP, in order to show a statistically meaningful difference in the mean BE (Alb) level among patients with severe preeclampsia with and without interstitial edema and with and without elevated ICP, we will need to recruit a total of 80 patients, with an alpha level of 0.05 and a power of 0.9. Furthermore, on the BE (Alb) scale, the mean BE (Alb) of the low albumin group (mean albumin of 2.2 g/dL) is approximately equal to a BE (Alb) of 4 meq/L and may represent an important clinical endpoint. Thus, assuming a normal distribution, 50% of this group is expected to have a BE (Alb) > 4 meq/L. The increased albumin group (mean albumin of 2.8 g/dL) lies approximately 1 standard deviation from the decreased albumin group, and assuming a normal distribution, we would expect 18% of this group to exceed the BE (Alb) > 4 meq/L cut point. Using these two proportions, a chi-squared test with a sample ratio of 3:1, power of 0.8, and alpha level of 0.05 will require a total sample size of 84 patients (21 with the ultrasound findings and 63 without findings).

Conditions
Pre-Eclampsia
Being tested
Ultrasound examination
Medical subject headings
Pre-Eclampsia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound examinationProcedure or surgery

    Also called ONSD, B-pattern, diastology

    echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Association BE(alb) and with delivery outcome

    Comparison number of patients with abnormal BE(alb) with number of patients undergoing emergency cesarean section (indicated through abnormal CTG).

    Measured: 24hours

  2. Correlation BE(alb) with comet score and optic nerve sheath diameter (ONSD)

    correlation BE(alb) with comet score and optic nerve sheath diameter (ONSD)

    Measured: 24hrs

Secondary outcomes (2)
  1. Association B-pattern on lung ultrasound and delivery outcome

    Comparison number of patients with B-pattern on lung ultrasound with number of patients undergoing emergency cesarean section (indicated through abnormal CTG).

    Measured: 24hrs

  2. Association increased intracranial pressure (ICP) based on ONSD and delivery outcome

    Comparison number of patients with increased ICP (=ONSD>5.8mm) with number of patients undergoing emergency cesarean section (indicated through abnormal CTG).

    Measured: 24hrs

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2016 (estimated)
  2. Study startMar 2016
  3. Primary completionOct 2016
  4. Study completionOct 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
97 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02721771
Sponsor's protocol ID
UCapeTown
Status last verified
Apr 2017
First submitted
10 Mar 2016
Last updated
26 Apr 2017
Results posted
No
Data monitoring committee
No

Publications

  • Ortner CM, Krishnamoorthy V, Neethling E, Flint M, Swanevelder JL, Lombard C, Fawcus S, Dyer RA. Point-of-Care Ultrasound Abnormalities in Late-Onset Severe Preeclampsia: Prevalence and Association With Serum Albumin and Brain Natriuretic Peptide. Anesth Analg. 2019 Jun;128(6):1208-1216. doi: 10.1213/ANE.0000000000003759.

    PubMed 31094790

Questions about this trial

What is this clinical trial studying?

An observational study of Pre-Eclampsia, run by University of Cape Town at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Association BE(alb) and with delivery outcome (time frame: 24hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02721771, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in